Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 231Recruiting 131Unknown 85Active not recruiting 60Terminated 53Withdrawn 20Not yet recruiting 19Enrolling by invitation 6No longer available 4Approved for marketing 2Suspended 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 99Breast 59Other hematologic neoplasm 46Genitourinary 45CNS 44Lymphoid 43Thoracic 40Gynecologic 27Other solid neoplasm 25Tumor-Agnostic 24Dermatologic 23Head & Neck 21Sarcoma 18Myeloid 14Plasma cell 10Other 7Classical hematology 4Endocrine 3Other neoplasm 1NET 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × NET × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡